Goldman Sachs
SVNT

Goldman Sachs’s SAVIENT PHARMACEUTICALS INC SVNT Stock Holding History

Goldman Sachs’s Portfolio SVNT Stock Details SVNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-21,104
Closed -$13K – 7010
2013
Q3 		$13K Sell
21,104
-20,279
-49% -$13K ﹤0.01% 6471
2013
Q2 		$23K Buy
+41,383
New +$28.8K ﹤0.01% 6177

Other funds holding SVNT

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
FHC
First Heartland Consultants Lake St. Louis, Missouri $1.55B AUM 20.5% 1-Year Est. Return
PSC
Prentiss Smith & Co Brattleboro, Vermont $172M AUM 21.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Goldman Sachs's SVNT Position: Q4 2013 in Review

Goldman Sachs sold out of SAVIENT PHARMACEUTICALS INC (SVNT) in Q4 2013, closing a stake of 21,104 shares — an estimated $13K sold.

Goldman Sachs first reported a position in SVNT in Q2 2013 and held it in 2 quarters. The position peaked at $23K in Q2 2013. 7 funds tracked by Wall St. Rank hold SVNT as of Q4 2013.

  • Goldman Sachs reported no remaining SAVIENT PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Goldman Sachs sold 21,104 SAVIENT PHARMACEUTICALS INC shares in Q4 2013, an estimated $13K.
  • Goldman Sachs first reported a position in SAVIENT PHARMACEUTICALS INC in Q2 2013 and held it in 2 quarters.
  • Goldman Sachs's SAVIENT PHARMACEUTICALS INC position peaked at $23K in Q2 2013.
  • 7 funds tracked by Wall St. Rank held SAVIENT PHARMACEUTICALS INC as of Q4 2013.

Based on Goldman Sachs's 13F filing for Q4 2013, filed 14 Feb 2014.